Figure 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Grade 3 to 4 treatment-related AEs over time by KRAS and assigned treatment. Rates of treatment-related AEs with 95% CI by treatment and KRAS-variant status, with KRAS-variant patients being depicted by blue (cisplatin-treated) and red (cetuximab-treated) and nonvariant patients depicted by green (cisplatin-treated) and brown (cetuximab-treated).
Fields of Study & Subjects
Head and Neck Cancer Studies
Esophageal Cancer Research and Treatment
Oral health in cancer treatment
Publication details
- Publication date
- 31 March 2026
- Language
- EN